The Role of HPV Elimination in Cervical Cancer Prevention Strategies

Understanding the Impact of HPV on Cervical Cancer

In 2020, global statistics on cervical cancer revealed that there were approximately 604,127 cases, with an alarming 341,831 resultant deaths. The Human Papillomavirus (HPV), which is predicted to affect around 300 million people annually, poses a significant public health concern. Japan is not exempt from this crisis; as of 2019, approximately 29,136 cases were reported annually, leading to 6,818 deaths by 2021. If these trends persist, an estimated 44 million new cervical cancer cases may emerge worldwide over the next fifty years.

Eliminating HPV could dramatically impact the prevention and treatment of HPV-related diseases, particularly cervical cancer. Currently, common standard treatments for high-grade cervical intraepithelial neoplasia (CIN) include conization and simple hysterectomy. However, these surgical options carry risks such as reduced fertility, miscarriage, or preterm birth, raising significant quality of life (QOL) concerns for patients. These issues also intersect with broader social challenges, particularly in the context of declining birth rates, posing far-reaching implications for society at large.

Research Objectives

Our primary goal has been to eliminate HPV and preemptively address the subsequent development of HPV-related diseases, including high-grade CIN. Our research has spanned 37 years, focusing on developing conservative and sustainable treatment options that minimize physical burdens and fertility risks for patients. This initiative forms the capstone of our prolonged research efforts and aims at enhancing future medical practices. However, I often grapple with the sentiment that despite the innovations I have contributed, I have not sufficiently returned these advancements to society, thus falling short of the patent system's intent.

Comments on HPV and Cancer Development

While HPV is a leading cause of cervical cancer, it is critical to understand that not every individual infected with HPV will develop cancer. The cancer progression involves multiple factors, and two significant approaches—the SIR-Method—can mitigate the risk of progression.

1. Eliminating the HPV Virus: Our research achieved an impressive HPV clearance rate of 84.6%.
2. Suppressing Lesion Progression: Even in the presence of residual HPV, we were able to normalize 98.7% of cytological abnormalities among the 15% of participants with lingering HPV.

These findings suggest that achieving either clearance or control of disease progression (or both) may help avert the development of cervical cancer. We examined approaches based on the SIR-Method (Scrape off and Inflammatory Reaction Method). It is widely recognized that immunity at HPV infection sites is often inadequate. Therefore, we hypothesized that scraping these sites could induce important antigen exposure and localized inflammatory responses, stimulating natural regression of HPV and improving lesions.

Clinical Information

Wavehira Ladies Clinic
Address: 2-17-1 Kyodo, Setagaya-ku, Tokyo 156-0005
Tel: 03-5477-0236
Fax: 03-5477-0327
Website: Wavehira Ladies Clinic

Important Patent Information:
1. Indian Patent: No. 510906 (December 24, 2020)
2. Domestic Patent: No. 6836047 (February 9, 2021)
3. Chinese Patent: No. CN306393309S (March 19, 2021)
4. Tokyo SMEs Foreign Patent Application Fee Grant Certification No. 3東中事知第542号 (October 11, 2021)

By understanding these dynamics and further developing effective strategies, we hope to significantly contribute to combating cervical cancer.